leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals welcomes eye care executive Grant Larsen as Chief Commercial Officer

Larsen has almost 20 years of senior management positions in North American eye care

Aequus Pharmaceuticals Inc. -
Larsen has a strong background in strategic leadership, most recently as the past CEO of Eye Recommend, one of Canada’s largest cooperatives of optometrists

Aequus Pharmaceuticals Inc (CVE:AQS) told investors that accomplished entrepreneur Grant Larsen had been hired as the company's chief commercial officer, effective August 17.

"The eye care medical market consisting of both prescription and OTC products is poised for double-digit growth, not only in Canada, but across North America," Larsen said in a statement.

READ: Aequus Pharmaceuticals completes C$2.5 million equity financing to launch its Evolve line of dry eye products

"My focus and the focus of our commercial team will be the launch of the Evolve line of eye drops and the continued growth in market share of our existing products."

Larsen has a strong background in strategic leadership, most recently as the past CEO of Eye Recommend, one of Canada’s largest cooperatives of optometrists. In addition, Larsen has also held senior positions at Allergan, Nikon Canada and Digital ECP.

He also has almost 20 years of senior management positions in North American eye care, said Aequus.

"We are delighted to have an accomplished entrepreneur and leader like Grant join our growing team,” said Aequus CEO Doug Janzen.

"As we prepare for the near-term launch of our Evolve line of eye care products we were looking for a Chief Commercial Officer with deep experience and relationships with Ophthalmologists, Optometrists and associated buyer groups and we are excited to welcome Grant to the team.”

Earlier this month, the group closed its previously announced public offering to raise around C$2.5 million in equity financing to raise funds to launch its Evolve preservative-free line of dry eye products.

Shares in Toronto added 3.57% to C$0.14 each.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Minotaur Exploration's Andrew Woskett highlights its technical credentials...

Minotaur Exploration's (ASX:MEP) Andrew Woskett speaks to Proactive's Andrew Scott soon after announcing they're to proceed with the acquisition of the Pyramid Gold project in north Queensland. The project is 180 kilometres south of Townsville, covers 150 square kilometres and includes two main...

6 hours, 11 minutes ago

2 min read